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Abstract
Background—The healthy microbiome protects against the development of Clostridium difficile 
infection (CDI), which typically develops following antibiotics. The microbiome metabolizes 
primary to secondary bile acids, a process if disrupted by antibiotics, may be critical to initiation 
of CDI.
Aim—To assess the levels of primary and secondary bile acids associated with CDI and associated 
microbial changes.
Methods—Stool and serum were collected from patients with (1) first CDI (fCDI), (2) recurrent 
CDI (rCDI) and (3) healthy controls. 16S rRNA sequencing and bile salt metabolomics were 
performed. Random forest regression models were constructed predict disease status. PICRUSt 
analyses were used to test for associations between predicted bacterial bile salt hydrolase (BSH) 
gene abundances and bile acid levels.
Results—60 patients (20 fCDI, 19 rCDI, and 21 controls) were enrolled. Secondary bile acids in 
stool were significantly elevated in controls compared to rCDI and fCDI (p<0.0001 and p=0.0007 
respectively). Primary bile acids in stool were significantly elevated in rCDI compared to controls 
(p<0.0001) and in rCDI compared to fCDI (p=0.02). Using random forest regression, we 
distinguished rCDI and fCDI patients 84.2% of the time using bile acid ratios. Stool deoxycholate 
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to glycoursodeoxycholate was the single best predictor. PICRUSt analyses found significant 
differences in predicted abundances of bacterial BSH genes in stool samples across the groups.
Conclusion—Primary and secondary bile acid composition in stool was different in those with 
rCDI, fCDI, and controls. The ratio of stool deoxycholate to glycoursodeoxycholate was the single 
best predictor of disease state and may be a potential biomarker for recurrence.
Keywords
Clostridium difficile; bile salts; microbiome
Background
Clostridium difficile is a spore-forming, potentially pathogenic organism that colonizes the 
human gut. Recurrent disease complicates 20–30% of cases and represents an important 
source of morbidity and mortality.1–3 The intestinal microbiota protects against the 
development of Clostridium difficile infection (CDI), and antibiotic-induced changes in the 
microbiota likely permit initiation of the disease. While toxins associated with this disease 
have been well characterized, the host microbial and metabolic alterations, which facilitate 
CDI, as well as their role in the disease and its recurrences, are not well understood.
The immediate cause of CDI is evident: the disease is communicated by ingestion of 
spores.4 Spores are resistant to heat and antibiotics and are able to survive outside of the 
colon. Spores germinate in the GI tract and become vegetative cells which can produce 
toxin.5 While the organism itself is noninvasive6, diarrhea is mediated by the release of 
toxin.7 However, the underlying pathogen-commensal interactions that gives rise to the 
resulting pseudomembranous colitis remains poorly defined.
Germination of spores is critical to initiate CDI. Bile acids are vital to the germination 
process. Primary bile acids are produced in the liver and released into the small intestine to 
assist in digesting fat5. A majority of bile acids are reabsorbed in the small intestine, 
however a portion are passed into the colon where they undergo biotransformations by 
intestinal bacteria.5 The normal intestinal microbiota metabolizes primary bile acids through 
7α-dehydroxylation and a series of other biochemical transformations.8 This process may be 
disrupted with antibiotics, producing an increase in primary bile acids and a reduction of 
secondary bile acids.9
The relationship between Clostridium difficile and bile acids is complex. In vitro studies 
suggest that the primary bile acids cholate, taurocholate and glycocholate can stimulate 
germination of C. difficile spores, however the primary bile acid chenodeoxyholate can 
inhibit germination.10 Additionally the secondary bile acid deoxycholate can also stimulate 
germination but more importantly deoxycholate inhibits growth of the vegetative form.11,12 
Antibiotic therapy is thought to ablate critical members of the commensal microbiota that 
generate inhibitory (protective) secondary bile acids. Stool extracts from antibiotic treated 
mice have been found higher concentrations of primary bile acids, whereas stool extracts 
from untreated mice have relatively higher secondary bile acids.9
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While the interaction between bile acids and CDI is illustrated in in vitro studies, the 
relationship between the host microbiome and bile salt metabolism is less well defined in 
humans with CDI.13 An understanding of this interaction is essential to identify those at 
greatest risk for recurrence, to develop better strategies to treat the disease and to prevent 
recurrences. We aim to delineate the relationship between bile acid concentration, host 
microbiome, and CDI status.
Methods
This is a cross sectional study of three well-defined groups: individuals experiencing their 
first episode of CDI (fCDI), individuals with recurrent CDI (rCDI) defined as 3 or more 
episodes, and healthy controls.
The rCDI group and healthy controls were recruited from patients and rigorously screened 
healthy donors who had been referred for fecal transplantation for recurrent CDI. Donor 
selection, screening for relevant communicable diseases, and stool processing were 
performed as outlined by the Fecal Microbiota Transplantation Working Group.14 The 
patients experiencing their first episode of CDI were recruited from the inpatient service at 
Brigham and Women’s Hospital informed by daily reports of patients with positive tests for 
C. difficile provided by the BWH Clinical Microbiology Laboratory.15,16 CDI testing was 
performed with an Elisa for Tox A/B and this was confirmed with PCR. After informed 
consent, stool and blood samples were collected from each patient. Controls were not 
exposed to antibiotics for a minimum of 3 months. Samples from fCDI patients were 
collected prior to initiation of antibiotics to treat CDI. For rCDI patients, samples were 
collected on stable doses of chronic oral vancomycin prior to fecal transplantation. Stool 
samples were flash frozen at −80° C within 4 hours. Clinical data was extracted from 
medical records and patient interview. Blood plasma and stool samples were analyzed for 
bile salt metabolomic profiles; and stool was sent for high-throughput 16S rRNA amplicon 
sequencing to determine the composition of the microbiota. Any patients on antibiotics for 
other reasons or those taking bile salt binding agents were excluded from the study. This 
protocol was approved by the institutional review board (IRB) at Brigham and Women’s 
Hospital.
Preparation of DNA and sequencing protocols
A multiplexed amplicon library covering the 16S rDNA gene V4 region was generated from 
human stool sample DNA. Bacterial genomic DNA was extracted using the Mo Bio Power 
Fecal DNA Isolation kit (Mo Bio Laboratories, Carlsbad, CA) according to the 
manufacturer’s instructions for high yields of DNA with the following modifications to 
increase yields from difficult to lyse microbes. An additional bead beater step using the 
Faster Prep FP120 (Thermo) at 6 meters/second for 1 min was used instead of vortex 
agitation. Incubation with buffers C2 and C3 was increased to 10 min at 4°C.
Starting nucleic acid concentrations were determined by a Qubit Fluromoter (Life 
Technologies, Carlsbad, CA). A multiplexed amplicon library covering the 16S rDNA gene 
V4 region was prepared using the protocol of with dual-index barcodes.17 The aggregated 
library pool was size selected from 300–500 bp on a pippin prep 1.5% agarose cassette 
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(Sage Science, Beverly, MA) according to the manufacturer’s instructions. The 
concentration of the pool was measured by qPCR (Kapa Biosystems, Willmington, MA) and 
loaded onto the MiSeq Illumina instrument (300 bp kit) at 6–9pM with 40% phiX spike-in to 
compensate for low base diversity according to Illumina’s standard loading protocol.
16S rRNA data analysis
Sequencing of the stool samples on Illumina MiSeq instrument generated 5,244,155 total 
raw sequencing reads. Raw reads were processed using the mothur software package (v.
1.34.2) and custom Python scripts, which perform denoising, quality filtering, alignment 
against the ARB Silva reference database of 16S rDNA gene sequences, and clustering into 
Operational Taxonomic Units (OTUs) at 97% identity.18 In total, 8,330 OTUs were 
generated. After filtering OTUs that failed to have a mean number of reads per sample ≥ 1 in 
at least one cohort, 597 OTUs were available for further analysis. To identify the OTUs with 
increased taxonomic resolution, the Pplacer software package was used to perform 
phylogenetic placement.19 Pplacer uses a likelihood-based methodology to place short 
sequencing reads of 16S rRNA amplicons on a reference tree, and also generates taxonomic 
classifications of the short sequencing reads using a least common ancestor-based algorithm. 
The reference tree required for phylogenetic placement was generated using full-length or 
near full-length (>1,200 nt) 16S rDNA sequences of type strains from the Ribosomal 
Database Project (RDP).20
A measure of overall microbial community diversity, the Shannon entropy18,21,22, was 
calculated for the samples, and the nonparametric Wilcoxon rank-sum test was applied for 
hypothesis testing.23 To visualize differences in overall microbial community structure, the 
unweighted Unifrac measure24 was calculated between all pairs of samples, and Principal 
Coordinates Analysis (PCoA) plots were generated using custom R scripts. Analysis of 
Molecular Variance (AMOVA) was used for statistical hypothesis testing18,25,26 of 
differences in overall microbial community structure between cohorts as assessed with the 
Unifrac measures. DESeq2 within the phyloseq package was applied to test for differential 
abundance of phyla and genera in different cohort groups.27 For all statistical testing for 16S 
rDNA data analysis, p-values were adjusted for multiple hypothesis testing using the method 
of Benjamini and Hochberg.28
To predict bile salt hydrolase gene content in the samples, 486 of the OTUs defined as 
described above, accounting for more than 97% of all reads, were mapped to OTUs defined 
in the 13_5 release of the Greengenes database whose representative sequences were at least 
99% identical to representative sequences of the OTUs.29 Relative abundances of those 
Greengenes OTUs were used to predict the abundances of genes corresponding to KEGG 
orthology K01442, cholylglycine hydrolase, with PICRUSt 1.0.0.30 OTUs contributing to 
changes in BSH abundance between groups were identified using the Pplacer results 
described above, and changes in abundances of those OTUs between groups were 
individually tested for significance using the Wilcoxon rank-sum test.
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Bile Salt Metabolomics
Bile acids were measured using liquid chromatography tandem mass spectrometry (LC-MS) 
method operated on a Nexera X2 U-HPLC (Shimadzu Scientific Instruments; Marlborough, 
MA) coupled to a Q Exactive hybrid quadrupole orbitrap mass spectrometer (Thermo Fisher 
Scientific; Waltham, MA) methods. Stool samples were homogenized in a weight 
proportional volume of water (4μL/mg of stool) using a TissueLyser II (Qiagen). Plasma or 
stool homogenates (30 μL) were extracted using 90 μL of methanol containing PGE2-d4 as 
an internal standard (Cayman Chemical Co.; Ann Arbor, MI) and centrifuged (10 min, 
10,000 × g, 4°C). The supernatants (10 μL) were injected onto a 150 × 2.1 mm ACQUITY 
UPLC BEH C18 column (Waters; Milford, MA). The column was eluted isocratically at a 
flow rate: 450μL/min with 20% mobile phase A (0.1% formic acid in water) for 3 minutes 
followed by a linear gradient to 100% mobile phase B (acetonitrile with 0.1% formic acid) 
over 12 minutes. MS analyses were carried out using electrospray ionization in the negative 
ion mode using full scan analysis over m/z 70–850 at 70,000 resolution and 3 Hz data 
acquisition rate. Additional MS settings were: ion spray voltage, −3.5 kV; capillary 
temperature, 320°C; probe heater temperature, 300 °C; sheath gas, 45; auxiliary gas, 10; and 
S-lens RF level 60. Targeted processing of a bile acid profiles was conducted using 
TraceFinder software (Thermo Fisher Scientific; Waltham, MA) and visually inspected for 
quality.
Additional statistical analyses
Baseline patient demographics differences were evaluated as mean ± SD for continuous 
variables. Bile acid concentrations were not normally distributed according to the Shapiro–
Wilk test; thus, the Wilcoxon rank-sum test with a bonferroni correction was used. The total 
of primary and secondary bile acids were calculated by averaging the concentration of all 
unconjugated and conjugated species. The relative proportion of a given acid corresponds to 
its concentrations divided by the total of bile acids. These statistical analyses were 
performed using SAS v.9.4.
Random forest regression models were constructed using the random forest R package with 
100,000 trees and two variables per branch. To construct each tree, a random selection of 2/3 
of the samples were used to train the model, and the remaining 1/3 used to test the model (3-
fold cross-validation). Study cohort groups were the dependent variables and either OTUs 
(597 total) or log-transformed bile acids (27 measured in blood and stool) and/or part-to-
whole ratios of bile acids (bile acid x/(bile acid x + bile acid y)) (351 total) were used as 
predictors. For samples with bile acid abundance below the limit of detection, the missing 
data was imputed using the MICE package in R. To assess the random forest model 
constructed, study groups were shuffled randomly and 100 random forest regressions were 
computed. The out-of-bag error estimate was compared to the un-shuffled dataset using a 
one sample Wilcoxon one sample signed rank test to assess the performance of the 
regression model.31
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Results
A total of 60 subjects were enrolled in the study: 21 controls, 19 rCDI subjects and 20 fCDI 
subjects. The rCDI group had an average of 3.6 (range 3–6) confirmed recurrences and these 
patients were all being screened for fecal transplantation. All rCDI patients were on chronic 
vancomycin at the time of collection. All but one of the fCDI patients were inpatients at 
Brigham and Women’s Hospital. The reasons for hospitalization varied and included rectal 
bleeding, abdominal pain, diarrhea, elective surgery, shortness of breath and alcohol 
withdrawal. Eleven of the 20 fCDI patients had not received antibiotics in the 8 weeks prior 
to diagnosis. Of the patients that did, the antibiotics given included clindamycin, 
ciprofloxacin, levofloxacin and cefpodoxime. None of the fCDI patients met criteria for 
severe or severe/complicated disease. Controls were all healthy patients who passed the fecal 
transplant donor screening clinical and laboratory assessment14. Groups did not differ 
greatly in their demographic characteristics, however controls were significantly younger 
then fCDI patients (47 ± 16.8 vs 66.6 ± 17.2, p=0.0007). Additionally, both fCDI and rCDI 
patients were more likely to be taking proton pump inhibitors compared to controls (9 vs 1, 
p=0.0025 and 12 vs 1 p <.0001 respectively) (Table 1). There were no significant 
relationships between proton pump inhibitor use and either bile salts or OTUs using 
spearmon correlation and random regression analysis.
Bile salt analysis
Stool bile acid analysis—The median secondary bile acids lithocholate and 
deoxycholate in stool were significantly elevated in controls compared to both fCDI (1.54E
+07 vs 2.26E+06, p=<0.0001 and 4.60E+07 vs 1.20E+07, p=0.0001 respectively) and to 
rCDI (1.54E+07 vs 2.71E+04, p=<0.0001 and 4.60E+07 vs 1.32E+05 p=<0.0001 
respectively). Additionally they were significantly elevated in fCDI vs rCDI (2.26E+06 vs 
2.71E+04, p=0.02 and 1.20E+07 vs 1.32E+05, p=<0.05 respectively). The primary bile 
acids cholate and chenodeoxycholate were significantly elevated in rCDI compared to 
controls (3.91E+07 vs 8.74E+06, p=0.001 and 1.07E+07 vs 7.18E+05, p=0.02 respectively) 
(Figure 1a). Patients with rCDI overall had a significantly higher abundance of primary bile 
salts then both fCDI and controls. Similarly, rCDI patients had significantly lower secondary 
bile salts then controls and fCDI(Figure 1b).
Plasma bile salt analysis—Individual primary bile acids from blood plasma were not 
significantly different between the groups (Figure 1a and 1b). Secondary bile acids were 
present in the blood but at lower abundances than in the stool. Median deoxycholic acid in 
the blood was significantly higher in fCDI than rCDI (1.54E+05 vs 6.12E+04, p=0.003) as 
well as significantly higher in controls than in both fCDI and rCDI patients respectively 
(3.41E+05 vs 1.54E+05, p=0.05 and 3.41E05 vs 6.12E+04, p<.0001).
Microbiome analyses
16S rRNA gene analyses revealed significant differences in ecological (alpha) diversity as 
measured by Shannon entropy (Figure 2). These differences were most pronounced with 
rCDI vs controls (adjusted p <0.001), however significant differences were also seen when 
comparing fCDI and rCDI (adjusted p <0.05) and controls and fCDI (adjusted p <0.05). 
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While variation occurred among the subjects, clear differences were seen in the phyla 
present in each cohort (Figure 3) with multiple significant differences between groups (Table 
2). Overall microbial community structure (beta diversity) differed significantly between all 
groups as measured by unweighted Unifrac analysis (Figure 4, p-values = 0.001).
Significant differences in relative abundances at the level of individual taxa were also 
observed. These differences were seen between all groups, notably between control and 
fCDI and even more profoundly between control and rCDI (Supplementary Table 1). In 
particular, statistically significant increases in abundances of multiple species in the Order 
Clostridiales in controls compared to both CDI groups were observed. Collinsella species (a 
member of phylum Actinobacteria) were also statistically significantly decreased in both 
fCDI and rCDI subjects compared to controls, members of which carry 7α-dehydrogenase 
enzymes with activity on bile acids, suggesting that the loss of these members may be 
associated with decreased abundance of secondary bile acids.32,33
To determine whether bile salts, OTUs or combinations thereof could serve as biomarkers 
distinguishing between fCDI and rCDI, we constructed random forest regressions of these 
variables against patient status (control, fCDI, or rCDI). The model including only OTUs 
had a 23.7% error rate, misclassifying 3/20 fCDI patients as rCDI and 6/19 rCDI patients as 
fCDI. This model, which takes into account all OTU abundances, ranks Enterobacteriaceae 
and Lactobacillus OTUs (OTUs resolved at different levels) as the most important variables 
for predicting patient status, both of which are increased in relative abundance in rCDI 
relative to fCDI patients.
When using bile salts only as predictors, the best indicators of disease status are the 
secondary serum bile acids taurodeoxycholate and glyodeoxycholate, with an error rate of 
21.05%. However, when part-to-whole ratios of bile salts are added in the model, the error 
rate improves to 15.8%, with the ratio of stool deoxycholate (a secondary bile acid) to stool 
glycoursodeoxycholate (a conjugated secondary bile acid) being the best predictor of rCDI 
versus fCDI, with this ratio significantly decreased in most rCDI patients. We evaluated the 
performance of this classification model by constructing an ROC curve, which suggests that 
measured bile acid levels perform better than chance in discerning rCDI from fCDI patients 
(Figure 5a). Using this ratio alone, it is possible to classify 84% of cases correctly, as only 
3/20 fCDI and 3/19 rCDI patients are misclassified (Figure 5b). The top two OTUs 
predicting patient status, Enterobacteriaceae and Lactobacillus OTUs, are the only OTUs 
strongly negatively correlated with this ratio, suggesting that either the deoxycholate/
glycoursodeoxycholate ratio or Enterobacteriaceae and Lactobacillus OTUs could be used as 
potential biomarkers for disease status.
To assess the levels of bacterial salt hydrolase genes present in samples, we applied 
PICRUSt30, a tool that predicts the abundances of bacterial genes using 16S rRNA 
sequencing data. The median predicted BSH gene abundance in the rCDI group was 19% of 
the median value in the control group (p<0.001), and was also significantly lower than the 
fCDI group (p<0.001). In contrast, there were no significant differences between predicted 
bile salt hydroloase gene abundances in control and fCDI groups. The difference in 
predicted bile salt hydrolase gene abundance between the control group and the rCDI group 
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was found to be largely the result of changes in the abundances of ten bacterial taxa (Table 
3). Taxonomic classifications for these OTUs are listed in Supplementary Table 2. Predicted 
bile salt hydrolase abundances were significantly correlated with bile acid levels. 
Specifically, predicted bile salt hydrolase abundances were negatively correlated with the 
conjugated and unconjugated forms of the primary acids, but positively correlated with the 
secondary acids (Table 4).
Discussion
In this study, we demonstrate that significant differences in bile salt profiles are associated 
with the first episode of CDI as well as recurrent CDI. Microbiome analyses further 
identified underlying alterations of the microbiota associated with CDI, and an association 
with reduced predicted bacterial bile salt hydrolase gene abundances that may be associated 
with a diminished capacity to metabolize bile acids.
A healthy intestinal microbiome prevents the development of CDI, though the mechanism of 
this colonization resistance has been uncertain. This study provides support for the role of 
secondary and primary bile salts in CDI. The protective effect of the healthy microbiome 
against the development of CDI may be through its metabolic effects on bile acids. In health, 
secondary bile acids predominate in stool, which are inhibitory to the germination of C 
difficile spores. It has been hypothesized that antibiotics, by reducing a subset of bacteria 
with enzymatic capability of producing secondary bile acids, diminishes the metabolic 
capacity of the microbiome. A reduction in bile salt metabolizing enzymes leads to an 
increase in primary bile salts, which are permissive to the germination of C difficile spores, 
culminating in CDI.34,35
It has been previously demonstrated by Weingarden et al. that FMT done for rCDI induced 
dramatic changes in fecal bile acid composition.36 Specifically two primary bile acids, 
cholic acid and chenodoxycholic acid, were significantly elevated in patients prior to FMT 
but were absent post-FMT and were also absent in the donor stool samples. Additionally, 
secondary bile acids that were absent pre-FMT were identified in the post-FMT samples. In 
this study we were able to build on this previous data and target a group of particular 
interest, those experiencing their first episode of CDI. Additionally, we were able to capture 
data from these patients prior to the initiation of antibiotics for treatment of C. difficle. 
Understanding the gut microbial and metabolic changes that occur even at the time of 
diagnosis of CDI may allow us to identify those at highest risk for recurrence and act earlier 
with fecal transplantation or other more targeted therapies in the future. This would prevent 
the significant morbidity of recurrent CDI but also reduce the cost these patients generate 
with multiple courses of vancomycin and hospitalizations.37
The relationship between bile salts and C. difficile spore germination has been well 
documented in vitro. Sorg et al reported that C. difficile spores can germinate in the presence 
of taurocholic acid.10,38 While a wide variety of bacterial species contain bile salt 
hydrolases, a smaller subset of organisms possess 7α-dehydroxylase and it’s associated 
enzymatic reactions which lead to the complete conversion of primary bile salts to secondary 
bile salts.39,40 Recently, Buffie et al identified a microbial cluster felt to be protective against 
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CDI.13 Specifically, they identified Clostridium scindens, a species with known 7α 
dehydroxylase activity41,42, as being protective against CDI. An OTU identified as C. 
scindens was present in only a minority of subjects in this study, at very low abundances, 
making it difficult to assess its relationship to bile salt levels; it is likely only one of several 
microbial species that perform this function in vivo. Additionally, we identified 10 OTUs 
that accounted for 67.3% of the decrease in predicted bile salt hydrolase abundance in rCDI 
patients compared to controls (table 2). This suggests that a core group of bacterial species 
may possess the majority of bile salt metabolizing capabilities and pending how much of this 
functional capacity is knocked out with the use of broad spectrum antibiotics, is a key 
determining factor in who will clear CDI and who will go on to recur.
We evaluated the utility of bile acid profiles to predict the clinical phenotype of patients, i.e., 
control, fCDI, or rCDI. Specifically, the secondary bile acids taurodeoxycholate and 
glycodeoxycholate in the plasma were the best predictors of disease status when considering 
all bile acids as factors in the model. In addition, when ratios were included in the model, 
the part-to-whole ratio of deoxycholic acid and glycoursodeoxycholic acid in the stool were 
the most effective predictors of cohort membership. Therefore this ratio may serve as 
potential biomarkers for recurrence as this ratio was able to distinguish between fCDI and 
rCDI with higher accuracy than serum taurodeoxycholate and glycodeoxycholate as 
individual factors. We cannot confirm the validity of these potential biomarkers in this cross 
sectional study and recognize that a error rate of 15% remains significant. Prospective 
studies are needed to identify the sensitivity and specificity of these biomarkers in predicting 
recurrence at the time of first CDI which would allow clinicians to identity those at high risk 
much earlier in their course.
Additionally, these individual bile acids and ratios provide further mechanistic insight into 
the roles bile acids may be playing in rCDI, given the significant reduction of secondary bile 
acids in the rCDI cohort. These finding raise additional questions about the potential for 
modifying bile acids to be utilized as a therapeutic agent to treat CDI, especially rCDI. 
Further studies testing the therapeutic potential of secondary bile acids as a novel therapeutic 
agent would help elucidate whether they have a direct protective effect in treating and also 
preventing rCDI.
It is important to note the limitations of this study. The rCDI samples were all collected 
while patients were on chronic antibiotic therapy. Chronic vancomycin therapy may explain 
the decreased microbial diversity and shift in bile salts. However, patients experiencing 
recurrent CDI are almost always on chronic antibiotic therapy, so our study may well reflect 
the metabolic state of the colon underlying CDI recurrence. In addition, the fCDI samples in 
our study were all collected prior to antibiotic therapy, and these samples demonstrate 
similar trends to those of rCDI patients. Another limitation of our results is the cross-
sectional nature of the study; we do not have follow up data to conclude which, if any, of the 
fCDI patients experienced a recurrence. We were also unable to control for diet. We did 
collect dietary information, additionally all donors were household contacts of the rCDI 
patients with similar diets. We were not able to control for fCDI patient diets however. 
Further directed studies will be necessary to determine if the observed metabolomic 
derangements represent a cause or effect of the CDI.
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In conclusion, these results re-confirm our prior knowledge of the mechanistic role gut 
microbiota play in converting primary to secondary bile salts, which in health protect against 
CDI. When antibiotics kill commensal bacteria, which carry the ability to perform 7α-
dehydroxylation, an abundance of primary bile salts likely is a permissive factor for 
recurrent disease. This is the first study in humans to investigate the role of bile salt profiles 
in patients experiencing their first episode of CDI who are antibiotic naïve in order to better 
understand the genesis of this process. We have also suggested the role of secondary bile 
salts in stool as possible novel biomarkers of recurrence. These insights may help identify 
those at highest risk for recurrent disease and support the development of new treatments 
that target bile salt metabolism.
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Figure 1. 
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Figure 2. 
Shannon Entropy Analysis of Microbial Ecological Diversity. P-values from Wilcoxon-Man-
Whitney test. Adjusted p-values collected for multiple hypothesis testing using the method 
of Benjamini-Hochberg (22).
*Denotes adjusted-p-value <0.05
**Denotes adjusted-p-value < 0.001
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Figure 3. 
Relative abundances of microbial phyla in each subject (Control subjects n=21, First time 
subjects n=20, Recurrent subjects n=19).
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Figure 4. 
Beta diversity of gut microbiome in all subjects. Beta-diversity values were calculated using 
the unweighted Unifrac dissimilarity measure, to assess differences in overall microbial 
community structure. Overall community structure differed significantly between all groups, 
considered pairwise (adjusted p-values = 0.001), using Analysis of Molecular Variance for 
statistical hypothesis testing.
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Figure 5. 
Random forest model accurately assigns patients to groups based on bile acid part-to-whole 
ratios, (a) ROC curve for the random forest regression using bile acid part-to-whole ratios as 
independent variables where false positive rate is the incidence of assigning rCDI as fCDI 
and true positive rate is the incidence of assigning rCDI as rCDI. (b) ratio of deoxycholate to 
glycoursodeoxycholate and deoxycholate, which was found to be the most important 
predictor variable in the random forest model.
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Table 1
Patient Characteristics
Recurrent CDI
N=19
First Time CDI
N=20
Controls
N=21
P-Value
Age -mean +/− SD 56.8 +/− 16.2 66.6 +/− 17.2 47 +/− 16.8 0.002
White n(%) 17 (89.5) 14 (73.7) 19 (85.3) 0.51
Male n(%) 10 (45.5) 8 (42.1) 5 (26.3) 0.42
BMI mean +/− SD 24.1 +/− 5.3 28.2 +/− 1.1 28.6 +/− 1.4 0.05
Cholecystectomy n(%) 0 (0) 1 (5.2) 1 (4.5) 0.61
Dietary 0.27
Restrictions %(n)
  Gluten Free 1 (5.26) 0 (0) 1 (4.55)
  Lactose Free 2 (10.5) 0 (0) 0 (0)
  Vegetarian 0 (0) 1 (5.2) 0 (0)
On PPI n(%) 63.2 (12) 47.4 (9) 4.5 (1) <0.001
Current Smoker n(%) 15.8 (3) 10.5 (2) 9.1 (2) 0.40
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Table 2
Phyla showing significant differences among the cohort groups using DESeq2. Stated p-values were adjusted 
for multiple hypothesis testing using the method of Benjamini-Hochberg (22).
Cohort Groups Phylum Name log2FoldChange Adjusted p-values
Controls Compared to fCDI
Higher in Controls Actinobacteria −2.408 0.0004
Higher in Controls Verrucomicrobia −1.533 0.0042
Higher in fCDI Fusobacteria 1.644 0.0342
Higher in fCDI Synergistetes 2.195 0.0004
Higher in fCDI TM7 1.186 0.0381
Controls Compared to rCDI
Higher in Controls Euryarchaeota −2.000 0.0076
Higher in Controls Verrucomicrobia −1.031 0.063
Higher in Controls Actinobacteria −2.624 0.0001
Higher in Controls Bacteroidetes −2.381 0.0004
Higher in rCDI TM7 1.466 0.011
Higher in rCDI Fusobacteria 7.300 0
Higher in rCDI Proteobacteria 3.870 0
rCDI compared fCDI
Higher in fCDI Bacteroidetes −2.249 0.0008
Higher in fCDI Euryarchaeota −2.848 0.0001
Higher in fCDI Synergistetes −2.293 0.0005
Higher in rCDI Proteobacteria 2.986 0
Higher in rCDI Fusobacteria 5.656 0
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Table 4
Spearman correlation coefficients and p-values for predicted BSH genes and bile acid abundances in patient 
stool samples.
Correlation Coefficient P-value Bile Acid
Primary Bile Acids
−0.39 0.0029 chenodeoxycholate
−0.52 4.50E-05 taurochenodeoxycholate
−0.58 3.80E-06 Glycochenodeoxycholate
−0.42 0.0014 Cholate
−0.48 0.00017 Taurocholate
−0.58 3.90E-06 Glycocholate
Secondary Bile Acids
0.46 0.00064 lithocholate
0.43 0.0011 Deoxycholate
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